Day 1 Resources
2nd Advanced Life Sciences Institute – Intro Day 1
Panel 1 | Impacts of AI’s Rapid Rise in the Life Sciences
- Impacts of AI – Title Slide & Speaker Cards
- InSilico – Nature Biotech – A small molecule TNIK inhibitor targets fibrosis in preclinical and clinical models
- Tibbetts – Can I get IP for my healthtech AI
- USPTO AI Inventorship Guidance
- USPTO Request for Comments 043024 – AI
Panel 2 | Licensing and Deals Update: Universities and Private Parties
- Licensing and Deals – Title Card & Speaker Cards
- Daniel, Ryan – Inflation Reduction Act
- Suzuki, Georgina – AI in Life Sciences Collaborations
- Trattner, Todd – Royalty Finance Overview
Panel 3 | Life Sciences Funding Models and Mechanisms
- Funding Models and Mechanisms – Title Slide & Speaker Cards
- Norviel, Vern – Life Science Funding Models
Panel 4 | Amgen One Year Out: What Have We Learned?
- Amgen One Year Out: What Have We Learned? – Slide Deck
- Amgen Inc v Sanofi
- Amgen v Sanofi transcript
- Baxalta Incorporated v Genentech Inc
- Regeneron Pharmaceuticals Inc v Mylan Pharmaceuticals Inc
- Teva Pharmaceuticals International GmbH v Eli Lilly and Company
- USPTO Guidance – Enablement (011024)
Panel 5 | Obviousness-Type Double Patenting post-Cellect: Strategies and Best Practices
- Obviousness-Type Double Patenting post-Cellect: Strategies and Best Practices – Title Slide & Speaker Cards
- Obviousness Type Double Patenting Post-Cellect Slide Deck
- Poon, Meghan – Patent Term Adjustment Takes a Hit in Cellect Decision _ MoFo Life Sciences
- In re Cellect
Panel 6 | Anti-Counterfeiting & Patient Safety
- Anti-Counterfeiting & Patient Safety – Title Slide & Speaker Cards
- Mayall, Lori – Anti-Counterfeiting & Patient Safety
- Yin, Eva – Anti-Countering and Patient Safety
- Light, David – Drug Quality & Safety Issues in the US and Health- System Strategies to Address Them
Day 2 Resources
2nd Advanced Life Sciences Institute – Intro Day 2
Panel 1 | Interplay of Patent and Regulatory Exclusivity – National and Global Considerations
- Interplay of Patent and Regulatory Exclusivity- Title Slide & Speaker Cards
- Hatch-Waxman, GAIN Act, Orphan-Drug, and Pediatric Exclusivities- Covington
- 180-Day Generic Drug Exclusivity – Forfeiture
Panel 2 | Future Pandemic Preparedness – Use of IP and Data
- Future Pandemic Preparedness – Title Slide & Speaker Cards
- Recent History of Pandemic Preparedness & Response- COVID-19 and the COVAX Effort
- Legal/Policy Issues Affecting Access to Medical Interventions in Pandemic
- A systematic review of barriers to data
- Finding equipoise CEPI revises its equitable access policy
- Funding the Development and Manufacturing of COVID-19 vaccines
- Independent Monitoring and Pandemic Treaty
- Omnibus CEPI Article on Developing Vaccines in Pandemic
- Rapid sharing of COVID-19 research
Panel 3 | Trade Secrets v. Patents – Key Strategic Decisions